Document Detail


Effects of 12-month valsartan therapy on glycation and oxidative stress markers in type 2 diabetic subjects with hypertension.
MedLine Citation:
PMID:  19075484     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Although it has been reported that angiotensin II receptor blockers inhibited the formation and accumulation of advanced glycation endproducts (AGEs) in vitro and in vivo, whether they can do so clinically is not clear. We investigated the effects of 12-month valsartan therapy on various markers of inflammation, glycation, and oxidation in type 2 diabetic subjects with hypertension. We started 40 mg/day valsartan treatment in 15 type 2 diabetic patients with hypertension. In 6 patients, the dose of valsartan was increased to 80 mg/day after 6 months and maintained until 12 months. Metabolic parameters including BMI and serum high molecular weight (HMW)-adiponectin, high-sensitivity C-reactive protein (hs-CRP) as an inflammation marker, AGEs, paraoxonase activity, platelet-activating factor (PAF)- acetylhydrolase activity, and urine 8-isoprostane levels were measured at baseline and after 6 and 12 months of treatment. Urine microalbumin level and carotid artery intima-media thickness (IMT) were also measured. Even after valsartan therapy, the blood pressure levels of the patients were not decreased significantly. Serum AGEs and urine 8-isoprostane levels decreased at both 6 and 12 months (P < 0.05 for both), although other metabolic and oxidative markers were unchanged. Though urine microalbumin levels tended to be decreased after 6 and 12 months of valsartan treatment, the changes were not significant. Mean IMT at 12 months was not changed from the baseline value. In conclusion, the findings suggest that treatment with valsartan, even at a low dose, may ameliorate some glycation and oxidative stress markers independently of an effect on blood pressure in hypertensive type 2 diabetic subjects.
Authors:
Naoko Komiya; Hiroshi Hirose; Yoshifumi Saisho; Ikuo Saito; Hiroshi Itoh
Related Documents :
20136764 - Effects of a 12-week intervention period with football and running for habitually activ...
15154954 - Post-challenge hyperglycaemia is an independent risk factor for arterial stiffness in j...
17329914 - Hyperglycemia promotes microinflammation as evaluated by c-reactive protein in the very...
19817934 - Safety and feasibility of achieving lower systolic blood pressure goals in persons with...
22292564 - Nonlinear fractal dynamics of human colonic pressure activity based upon the box-counti...
6748224 - The sequence and correlation of the changes in several parameters of energy metabolism ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International heart journal     Volume:  49     ISSN:  1349-2365     ISO Abbreviation:  -     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-12-16     Completed Date:  2009-02-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101244240     Medline TA:  Int Heart J     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  681-9     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Alkyl-2-acetylglycerophosphocholine Esterase / blood
Adiponectin / blood
Aged
Albuminuria / urine
Antihypertensive Agents / administration & dosage,  therapeutic use*
Aryldialkylphosphatase / blood
Biological Markers / analysis*
C-Reactive Protein / analysis
Carotid Arteries / pathology
Diabetes Mellitus, Type 2 / metabolism*
Dinoprost / analogs & derivatives,  urine
Female
Glycosylation End Products, Advanced / blood*
Humans
Hypertension / complications*
Male
Middle Aged
Oxidative Stress / physiology*
Tetrazoles / administration & dosage,  therapeutic use*
Valine / administration & dosage,  analogs & derivatives*,  therapeutic use
Chemical
Reg. No./Substance:
0/Adiponectin; 0/Antihypertensive Agents; 0/Biological Markers; 0/Glycosylation End Products, Advanced; 0/Tetrazoles; 137862-53-4/valsartan; 27415-26-5/8-epi-prostaglandin F2alpha; 551-11-1/Dinoprost; 7004-03-7/Valine; 9007-41-4/C-Reactive Protein; EC 3.1.1.47/1-Alkyl-2-acetylglycerophosphocholine Esterase; EC 3.1.8.1/Aryldialkylphosphatase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of white coat hypertension with metformin.
Next Document:  The profile and prognosis of patients hospitalised with heart failure. The value of discharge blood ...